Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 99,000 shares of Class A ...
Vera ( VERA ) Q2 Net Loss Widens 127%
Vera Therapeutics ( NASDAQ:VERA ) , a biotechnology company developing treatments for serious immunologic diseases, released results for the quarter on August 5, 2025. The most notable news was its widening net loss to $76.5 million, or $1.20 per share ( GAAP ) , compared to analyst expectations ...
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Allogene Therapeutics ( NASDAQ:ALLO ) , AvalonBay Communities ( NYSE:AVB )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. JP Morgan analyst Brian Cheng downgraded the rating for Allogene Therapeutics, Inc.
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif. , July 10, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 133,500 shares of Class A common stock and restricted ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., June 09, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted ...
Crude Oil Gains 2%; ABM Industries Shares Plunge After Q2 Results - ABM Indus ( NYSE:ABM ) , Docusign ( NASDAQ:DOCU )
U.S. stocks traded higher midway through trading, with the Nasdaq Composite jumping more than 1% on Friday. The Dow traded up 1.05% to 42,765.32 while the NASDAQ gained 1.31% to 19,551.81. The S&P 500 also rose, gaining, 1.10% to 6,004.74. In trading on Friday, utilities stocks fell by 0.2%.
Dow Jumps Over 500 Points; Nonfarm Payrolls Top Estimates - Davis Commodities ( NASDAQ:DTCK ) , EPWK Holdings ( NASDAQ:EPWK )
U.S. stocks traded higher this morning, with the Dow Jones jumping more than 500 points on Friday. Following the market opening Friday, the Dow traded up 1.29% to 42,867.21 while the NASDAQ gained 1.34% to 19,557.93. The S&P 500 also rose, gaining, 1.17% to 6,008.98.
Lululemon Cuts Earnings Forecast, Joins DocuSign, Samsara And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Braze ( NASDAQ:BRZE ) , Docusign ( NASDAQ:DOCU )
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Friday. Shares of lululemon athletica inc. LULU fell sharply in today's pre-market trading after the company cut its FY25 GAAP EPS guidance below estimates.
Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May - Applied Digital ( NASDAQ:APLD ) , Lyra Therapeutics ( NASDAQ:LYRA )
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 0.2% on Monday. The Dow traded down 0.49% to 42,064.07 while the NASDAQ rose 0.21% to 19,154.77. The S&P 500 also fell, dropping, 0.11% to 5,905.30. In trading on Monday, real estate stocks fell by 1.5%.
Vera Therapeutics Releases Trial Data, Stock Price Soars - Vera Therapeutics ( NASDAQ:VERA )
Atacicept led to a 42% reduction in UPCR versus placebo at week 36 ( p<0.0001 ) in adults with IgAN. Participants saw a 46% proteinuria drop from baseline with atacicept in the ORIGIN Phase 3 trial. Get access to the leaderboards pointing to tomorrow's biggest stock movers.
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy - Vera Therapeutics ( NASDAQ:VERA )
Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria ( UPCR ) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 ( p<0.0001 )
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
BRISBANE, Calif., June 02, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that the primary endpoint was met in the ORIGIN Phase 3 trial of atacicept for the treatment of immunoglobulin A nephropathy ( IgAN ) in adults.
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., May 09, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc.
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., April 09, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc.
Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch - Vera Therapeutics ( NASDAQ:VERA )
ORIGIN 3 fully enrolled with 431 participants to assess atacicept in IgAN over 104 weeks Primary data readout on proteinuria reduction expected this quarter from 36-week interim Feel unsure about the market's next move?
Nephrologists Embrace Earlier, More Aggressive IgAN Treatment as Branded Therapies from Calliditas, Travere, and Novartis Continue to Gain Traction, According to Spherix Global Insights
EXTON, PA, March 26, 2025 ( GLOBE NEWSWIRE ) -- Nearly all nephrologists agree that early and aggressive intervention is essential for improving outcomes in IgA nephropathy ( IgAN ) .
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., March 11, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that on March 6, 2025, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 51,500 shares of Class A common stock and restricted ...
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc.
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
BRISBANE, Calif., Feb. 26, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business ...
This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Expand Energy ( NASDAQ:EXE ) , Catalyst Pharmaceuticals ( NASDAQ:CPRX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Top 3 Health Care Stocks That Could Blast Off This Quarter - Vera Therapeutics ( NASDAQ:VERA ) , RadNet ( NASDAQ:RDNT )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
What's Going On With Vera Therapeutics Stock? - Vera Therapeutics ( NASDAQ:VERA )
Vera Therapeutics shares are trading lower by 7.3% Monday afternoon. Vera Therapeutics Inc VERA shares are trading lower by 7.3% to $34.31 Monday afternoon. The company announced an exclusive license agreement with Stanford University for VT-109.
Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., Jan. 13, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc.
Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 07, 2025 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., Dec. 09, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that on December 3, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 171,750 shares of Class A common stock and ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., Nov. 22, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that on November 18, 2024, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of a non-qualified stock option to purchase 108,000 shares of ...
Wall Street Analysts Think Vera Therapeutics ( VERA ) Could Surge 27.26%: Read This Before Placing a Bet
The consensus price target hints at a 27.3% upside potential for Vera Therapeutics (VERA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Vera Therapeutics to Participate at Upcoming Investor Conferences
BRISBANE, Calif., Nov. 08, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's ...
Vera Therapeutics to Participate at Upcoming Investor Conferences
BRISBANE, Calif., Nov. 08, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's ...
Vera Therapeutics to Participate at Upcoming Investor Conferences - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., Nov. 08, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc.
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., Oct. 29, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( "Vera" ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an ...
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
BRISBANE, Calif., Oct. 29, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( "Vera" ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an ...
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., Oct. 28, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( "Vera" ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a ...
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
BRISBANE, Calif., Oct. 28, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( "Vera" ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a ...
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years - Vera Therapeutics ( NASDAQ:VERA )
On Saturday, Vera Therapeutics Inc. VERA released data from its ORIGIN Phase 2b trial of atacicept in immunoglobulin A nephropathy ( IgAN ) , which showed stabilized kidney function through 96 weeks of long-term follow-up.
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - PROCEPT BioRobotics ( NASDAQ:PRCT )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Monday. Shares of PROCEPT BioRobotics Corporation PRCT rose sharply during Monday's session after the company reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance.
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 - Vera Therapeutics ( NASDAQ:VERA )
Long-term improvements observed in the quartet of findings defining disease modification supports atacicept's potential to prevent kidney failure in patients with IgAN; Long-term results from the ORIGIN Phase 2b study were simultaneously published in the Journal of the American Society of ...
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
BRISBANE, Calif., Oct. 26, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced data from its ORIGIN ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., Oct. 04, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that on October 2, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 125,000 shares of Class A common stock and ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., Oct. 04, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc.
Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
BRISBANE, Calif., Oct. 02, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that long-term ...
Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024 - Vera Therapeutics ( NASDAQ:VERA )
Two informational posters for ORIGIN Phase 3 and ORIGIN Extend trials of atacicept in IgAN accepted for presentation at Kidney Week; In-person and virtual R&D Day to discuss expanded atacicept R&D activities scheduled to take place in New York on October 2;
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
BRISBANE, Calif., Oct. 02, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced expansion of its ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., Sept. 10, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc.
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday - Vaxcyte ( NASDAQ:PCVX )
U.S. stocks were lower, with the Nasdaq Composite falling around 2% on Tuesday. Shares of Vaxcyte, Inc.
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., July 05, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) today announced that on July 1, 2024, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of a non-qualified stock option to purchase 160,000 shares of Class A ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., July 05, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc.
BK Virus Infection Market to Witness Surge in Growth During the Study Period ( 2020-2034 ) | DelveInsight
The BK virus infection market is expanding due to increased awareness and advancements in diagnostic technologies. Rising kidney transplant procedures and the subsequent need for effective treatments and management of BK virus in immunocompromised patients are driving market growth.
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BRISBANE, Calif., June 07, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc. ( Nasdaq: VERA ) , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's ...
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - Vera Therapeutics ( NASDAQ:VERA )
BRISBANE, Calif., June 07, 2024 ( GLOBE NEWSWIRE ) -- Vera Therapeutics, Inc.
